Khandelwal Laboratories Pvt Ltd

Khandelwal Laboratories Pvt Ltd is an Indian pharmaceutical manufacturer headquartered in Mumbai, Maharashtra. The company operates as a private limited entity and is engaged in the development, production and marketing of pharmaceutical formulations across a wide range of therapeutic categories. Its portfolio typically includes tablets, capsules, syrups, injections and other dosage forms, serving both domestic Indian markets and, in some cases, export destinations. As a mid-sized Indian pharma player, Khandelwal Laboratories competes in the crowded generic and branded-generic segment, where scale, distribution reach and regulatory compliance are key differentiators. The company has built a presence in several therapeutic areas, including anti-infectives, analgesics, cardiovascular medicines, gastrointestinal products and vitamins, among others. Its manufacturing operations are aligned with Indian regulatory requirements, and the company has historically supplied products to hospitals, pharmacies and through distributor networks. The Indian pharmaceutical market is highly fragmented, with thousands of manufacturers ranging from large multinationals to small regional players. Khandelwal Laboratories occupies the mid-tier space, focusing on affordable medicines and maintaining a portfolio that addresses common chronic and acute conditions. While not among the largest listed pharmaceutical companies in India, it has sustained operations for decades, reflecting a stable niche in the domestic market. Ownership remains private, with the company structured as a private limited company under Indian law. Specific details about its current leadership, exact product list, revenue and export footprint are not publicly prominent, but the brand is recognized within Indian pharma trade circles as a long-standing supplier of generic formulations.

Khandelwal Laboratories Pvt Ltd was established in 1946 in Mumbai, India, during a period when the Indian pharmaceutical industry was beginning to expand its domestic manufacturing capabilities. The company was founded as a private limited entity and gradually developed a portfolio of pharmaceutical formulations for the Indian market. Through the latter half of the 20th century, Khandelwal Laboratories built a presence in the generic and branded-generic segments, supplying medicines across multiple therapeutic categories. Like many Indian pharma companies of its generation, it focused on import substitution and affordable healthcare, aligning with India's broader push for self-reliance in medicine production. The company has maintained a private ownership structure and has operated continuously for decades. While it has not achieved the scale of India's largest pharmaceutical multinationals, it has sustained a stable position in the domestic market, particularly in the supply of essential medicines to hospitals, clinics and retail pharmacies. In the 21st century, the Indian pharmaceutical sector has undergone significant regulatory and competitive changes, including stricter quality standards and the rise of large generic exporters. Khandelwal Laboratories has continued to operate within this environment, though detailed public information about its recent milestones, expansions or leadership transitions is limited.

• 1946

  Khandelwal Laboratories Pvt Ltd is founded in Mumbai, India.

Mid-tier Indian pharmaceutical manufacturer focused on affordable generic and branded-generic medicines for the domestic market.

Product categories. Generic pharmaceutical formulations · Branded generic medicines · Tablets and capsules · Syrups and oral liquids · Injectables

• 2026-01-01

  Aurobindo Pharma acquires Khandelwal Laboratories' non-oncology prescription business for Rs 325 crore[1]阿拉宾度制药以3.25亿卢比收购Khandelwal Laboratories非肿瘤处方药业务timesofindia.indiatimes.com

  Reported: 2026-01-01

  Aurobindo Pharma, through its wholly owned subsidiary Auro Pharma Limited, acquired the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd on a going concern, slump sale basis for a cash consideration of Rs 325 crore, effective January 1, 2026. The acquired business comprises 23 established brands across 67 SKUs and nine pipeline products in pain management and anti-infective segments, with a turnover of Rs 113.5 crore, and is supported by a field force of approximately 470 personnel and over 1,600 stockists across India.

1. 1阿拉宾度制药以3.25亿卢比收购Khandelwal Laboratories非肿瘤处方药业务timesofindia.indiatimes.com